HK Stock Market Move | KEYMED BIO-B (02162) rose more than 3%. The company's internationalization strategy has reached an important milestone as it signed an exclusive licensing agreement with Aeira.

KEYMED BIO-B (02162) surged over 3%, as of the time of writing, it rose 2.83%, reaching HKD 79.95, with a transaction volume of HKD 70.71 million. In news, KEYMED BIO-B announced that Kangnoa has signed an exclusive licensing agreement with multinational pharmaceutical company Aeira Pte. Ltd. (Aeira). The two parties will collaborate on the market registration and commercialization of Kangnoa's self-developed monoclonal antibody targeting IL-4RSpuquibai injection (trade name: Kangyueda) in Southeast Asia and Central Asia. According to the agreement, Kangnoa will receive an upfront payment as well as milestone payments upon the approval of market applications in different countries and commercialization milestone payments, and will have the right to receive royalties based on net sales of the product in the licensed territories at a rate of up to high double digits. The announcement stated that Aeira will be responsible for the registration and commercialization of Spuquibai injection in 11 countries in Southeast Asia (Brunei Darussalam, Cambodia, Indonesia, Lao People's Democratic Republic, Malaysia, Myanmar, the Philippines, Singapore, Thailand, Timor-Leste, Vietnam) and 5 countries in Central Asia (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan), totals 18 countries and regions, including the Hong Kong Special Administrative Region and the Macao Special Administrative Region. Kangnoa will continue to be responsible for the production and supply of Spuquibai injection for Aeira.